New hope for leukemia patients allergic to standard treatment
NCT ID NCT00590915
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study offered Erwinase to people with acute lymphoblastic leukemia (ALL) who had allergic reactions to common L-asparaginase drugs. The goal was to provide a safe alternative to continue cancer treatment. Participants were children and adults with ALL and a history of hypersensitivity to E. coli-derived asparaginase.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.